CN109289053B - 卡巴他赛-寡/聚乳酸偶联前药、制剂及其制备方法与应用 - Google Patents
卡巴他赛-寡/聚乳酸偶联前药、制剂及其制备方法与应用 Download PDFInfo
- Publication number
- CN109289053B CN109289053B CN201811155920.5A CN201811155920A CN109289053B CN 109289053 B CN109289053 B CN 109289053B CN 201811155920 A CN201811155920 A CN 201811155920A CN 109289053 B CN109289053 B CN 109289053B
- Authority
- CN
- China
- Prior art keywords
- cabazitaxel
- polylactic acid
- oligo
- prodrug
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000004626 polylactic acid Substances 0.000 title claims abstract description 107
- 229920000747 poly(lactic acid) Polymers 0.000 title claims abstract description 96
- 229940002612 prodrug Drugs 0.000 title claims abstract description 74
- 239000000651 prodrug Substances 0.000 title claims abstract description 74
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 claims abstract description 65
- 229960001573 cabazitaxel Drugs 0.000 claims abstract description 63
- 239000002105 nanoparticle Substances 0.000 claims abstract description 47
- 238000010168 coupling process Methods 0.000 claims abstract description 25
- 238000005859 coupling reaction Methods 0.000 claims abstract description 25
- 230000008878 coupling Effects 0.000 claims abstract description 24
- 239000003054 catalyst Substances 0.000 claims abstract description 6
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 6
- 230000009471 action Effects 0.000 claims abstract description 4
- 238000005886 esterification reaction Methods 0.000 claims abstract description 3
- 239000004698 Polyethylene Substances 0.000 claims description 17
- -1 polyethylene Polymers 0.000 claims description 17
- 229920000573 polyethylene Polymers 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical group CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 239000002245 particle Substances 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 7
- 239000003960 organic solvent Substances 0.000 claims description 7
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical group CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 229940041181 antineoplastic drug Drugs 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 abstract description 18
- 230000000694 effects Effects 0.000 abstract description 15
- 238000001727 in vivo Methods 0.000 abstract description 11
- 239000003814 drug Substances 0.000 abstract description 10
- 230000002829 reductive effect Effects 0.000 abstract description 8
- 229920000642 polymer Polymers 0.000 abstract description 5
- 230000008685 targeting Effects 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 229940079593 drug Drugs 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000008213 purified water Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 231100000682 maximum tolerated dose Toxicity 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 238000011580 nude mouse model Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 238000004627 transmission electron microscopy Methods 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000002390 rotary evaporation Methods 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 231100000820 toxicity test Toxicity 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 238000009827 uniform distribution Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010052804 Drug tolerance Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229960003668 docetaxel Drugs 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- 208000010658 metastatic prostate carcinoma Diseases 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 230000025090 microtubule depolymerization Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002723 toxicity assay Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000013298 xenograft nude mouse model Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811155920.5A CN109289053B (zh) | 2018-09-30 | 2018-09-30 | 卡巴他赛-寡/聚乳酸偶联前药、制剂及其制备方法与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811155920.5A CN109289053B (zh) | 2018-09-30 | 2018-09-30 | 卡巴他赛-寡/聚乳酸偶联前药、制剂及其制备方法与应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109289053A CN109289053A (zh) | 2019-02-01 |
CN109289053B true CN109289053B (zh) | 2020-10-13 |
Family
ID=65161344
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811155920.5A Active CN109289053B (zh) | 2018-09-30 | 2018-09-30 | 卡巴他赛-寡/聚乳酸偶联前药、制剂及其制备方法与应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109289053B (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103772686A (zh) * | 2012-10-26 | 2014-05-07 | 苏州雷纳药物研发有限公司 | 一种两亲性嵌段共聚物及其制备方法、以及该共聚物与抗肿瘤药物形成的胶束载药*** |
CN104490797A (zh) * | 2014-12-22 | 2015-04-08 | 深圳海王药业有限公司 | 一种多相稳定的白蛋白结合型卡巴他塞 |
CN104936622A (zh) * | 2012-12-28 | 2015-09-23 | 布莱德治疗有限公司 | 包封在颗粒中的靶向缀合物及其制剂 |
CN105640882A (zh) * | 2015-10-16 | 2016-06-08 | 姚俊华 | 一种卡巴他赛胶束载药***及其制备方法和应用 |
CN106432141A (zh) * | 2016-07-19 | 2017-02-22 | 浙江大学 | 卡巴他赛药物前体的制备方法和应用 |
CN106620714A (zh) * | 2016-10-28 | 2017-05-10 | 浙江大学 | 7‑乙基‑10‑羟基喜树碱‑聚合物偶联药物及其纳米制剂制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105315294B (zh) * | 2014-06-26 | 2018-05-01 | 王杭祥 | 7-乙基-10-羟基喜树碱药物前体及其制备方法和应用 |
-
2018
- 2018-09-30 CN CN201811155920.5A patent/CN109289053B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103772686A (zh) * | 2012-10-26 | 2014-05-07 | 苏州雷纳药物研发有限公司 | 一种两亲性嵌段共聚物及其制备方法、以及该共聚物与抗肿瘤药物形成的胶束载药*** |
CN104936622A (zh) * | 2012-12-28 | 2015-09-23 | 布莱德治疗有限公司 | 包封在颗粒中的靶向缀合物及其制剂 |
CN104490797A (zh) * | 2014-12-22 | 2015-04-08 | 深圳海王药业有限公司 | 一种多相稳定的白蛋白结合型卡巴他塞 |
CN105640882A (zh) * | 2015-10-16 | 2016-06-08 | 姚俊华 | 一种卡巴他赛胶束载药***及其制备方法和应用 |
CN106432141A (zh) * | 2016-07-19 | 2017-02-22 | 浙江大学 | 卡巴他赛药物前体的制备方法和应用 |
CN106620714A (zh) * | 2016-10-28 | 2017-05-10 | 浙江大学 | 7‑乙基‑10‑羟基喜树碱‑聚合物偶联药物及其纳米制剂制备方法 |
Non-Patent Citations (8)
Title |
---|
A novel cabazitaxel-loaded polymeric micelle system with superior in vitro stability and long blood circulation time;Xiaoxiong Han et al;《Journal of Biomaterials Science, Polymer Edition》;20160127;第1-33页 * |
Lactic acid oligomers (OLAs) as prodrug moieties;J. Kruse, et al;《Pharmazie》;20131231(第68期);第93-99页 * |
New Generation Nanomedicines Constructed from Self-Assembling Small-Molecule Prodrugs Alleviate Cancer Drug Toxicity;Hangxiang Wang et al;《AACR》;20171020(第77期);第6963-6974页 * |
Polylactide-tethered prodrugs in polymeric nanoparticles as reliable nanomedicines for the efficient eradication of patient-derived hepatocellular carcinoma;Hangxiang Wang et al;《Theranostics》;20180624;第8卷(第14期);摘要、第3950页左栏最后1段至右栏第2段、第3951页左栏第1-2段、补充材料第2页第1段至第4页第1段 * |
Qi Shuai et al.Self-assembling poly(ethylene glycol)-block-polylactide-cabazitaxel conjugate nanoparticles for anticancer therapy with high efficacy and low in vivo toxicity.《International Journal of Pharmaceutics》.2019,(第574期), * |
Structure-Guided Engineering of Cytotoxic Cabazitaxel for an Adaptive Nanoparticle Formulation: Enhancing the Drug Safety and Therapeutic Efficacy;Jianqin Wan et al;《Adv. Funct. Mater.》;20181109(第28期);第1-12页 * |
Y‑Shaped mPEG-PLA Cabazitaxel Conjugates: Well-Controlled Synthesis by Organocatalytic Approach and Self-Assembly into Interface Drug-Loaded Core-Corona Nanoparticles;Fethi Bensaid et al;《Biomacromolecules》;20130222(第14期);第1189-1198页 * |
聚乙二醇-b-聚乳酸末端官能团的合成及在卡巴他赛载药体系中的应用;于小杰,等;《高分子材料科学与工程》;20180630;第34卷(第6期);摘要、第42页左栏第1段、第1.5节、第2.1节、第3节 * |
Also Published As
Publication number | Publication date |
---|---|
CN109289053A (zh) | 2019-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Huo et al. | Synthesis and characterization of low-toxic amphiphilic chitosan derivatives and their application as micelle carrier for antitumor drug | |
Ko et al. | Tumoral acidic extracellular pH targeting of pH-responsive MPEG-poly (β-amino ester) block copolymer micelles for cancer therapy | |
Yang et al. | Synthesis and characterization of biotin modified cholesteryl pullulan as a novel anticancer drug carrier | |
Tang et al. | Design, preparation and evaluation of different branched biotin modified liposomes for targeting breast cancer | |
CN113398277B (zh) | 脂肪酸/脂肪醇-抗肿瘤物质前药及其自组装纳米粒的制备方法 | |
CN110218312B (zh) | 具有高效药物负载性能的聚合物的制备方法 | |
CN112089845B (zh) | 紫杉烷类药物-阿霉素前药自组装纳米粒及其应用 | |
CN109810092B (zh) | 含有一氧化氮供体的环状碳酸酯单体及其制备和应用 | |
CN109054000B (zh) | 一种基于聚水杨酸的纳米载药体系及其制备方法和应用 | |
JP6867084B2 (ja) | 新規な陽イオン性ポリホスファゼン化合物、ポリホスファゼン−薬物コンジュゲート化合物およびその製造方法 | |
CN112604002A (zh) | 二硫键桥连的多西他赛-脂肪酸前药及其自组装纳米粒 | |
CN111116521B (zh) | 茄尼醇修饰的紫杉醇前药及其制备方法和应用 | |
CN113264906B (zh) | 多西他赛二聚体小分子前药及其自组装纳米粒的构建 | |
CN111298132B (zh) | 一种树状分子吉西他滨自组装纳米前药及其制备方法和应用 | |
Zhang et al. | Hyperbranched amphiphilic polymer with folate mediated targeting property | |
CN104548124B (zh) | 一种水溶性可降解的抗肿瘤前药及其制备方法 | |
Yi et al. | Synthesis, characterization, and formulation of poly-puerarin as a biodegradable and biosafe drug delivery platform for anti-cancer therapy | |
CN109369625B (zh) | 一种原酸酯5-氟尿嘧啶前药分子、其制备方法及其酸敏感纳米粒和应用 | |
CN108836937B (zh) | 顺铂纳米药物制剂、制备方法和应用 | |
CN102727905B (zh) | 一种金纳米-紫杉醇结合物及其制备方法和应用 | |
CN109289053B (zh) | 卡巴他赛-寡/聚乳酸偶联前药、制剂及其制备方法与应用 | |
CN106620714B (zh) | 7-乙基-10-羟基喜树碱-聚合物偶联药物及其纳米制剂制备方法 | |
CN114796513A (zh) | 二硒键桥连多西他赛二聚体前药及其自组装纳米粒 | |
CN112656950B (zh) | 喜树碱类-聚己内酯偶联前药、制剂及其制备方法与应用 | |
CN104096237A (zh) | 一种Pluronics-紫杉醇两亲性大分子前药及其胶束制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240201 Address after: 312368 East Industrial Zone, Zhonglian Village, Daoxu Street, Shangyu District, Shaoxing City, Zhejiang Province (within Shaoxing Shangyu Dingxin Film and Television Equipment Co., Ltd.) Patentee after: Shaoxing Shunyuan Biotechnology Co.,Ltd. Country or region after: China Address before: 310027 No. 38, Zhejiang Road, Hangzhou, Zhejiang, Xihu District Patentee before: ZHEJIANG University Country or region before: China |